Cargando…

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals

Sorafenib is currently used as a standard treatment to suppress the progression of hepatocellular carcinoma (HCC), especially in advanced stages. However, patients who receive Sorafenib treatment eventually develop resistance without clear mechanisms. There is a great need for better efficacy of Sor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Junjie, Lin, Hui, Li, Gonghui, Sun, Yin, Shi, Liang, Ma, Wen‐Lung, Chen, Jiang, Cai, Xiujun, Chang, Chawnshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215679/ https://www.ncbi.nlm.nih.gov/pubmed/27668844 http://dx.doi.org/10.1002/ijc.30446

Ejemplares similares

TR(4) nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression
por: Jin, Ren’an, et al.
Publicado: (2018)

Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals
por: Xu, Junjie, et al.
Publicado: (2017)

IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy
por: Chai, Dafei, et al.
Publicado: (2022)

Expression of tSTAT3, pSTAT3(727), and pSTAT3 (705) in the epithelial cells of hormone‐naïve prostate cancer
por: Krzyzanowska, Agnieszka, et al.
Publicado: (2019)

JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
por: Mohrherr, Julian, et al.
Publicado: (2019)

The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals
por: Xu, Junjie, et al.
Publicado: (2016)

New therapy with ASC-J9(®) to suppress the prostatitis via altering the cytokine CCL2 signals
por: Lin, Shin-Jen, et al.
Publicado: (2016)

Direct targets of pSTAT5 signalling in erythropoiesis
por: Gillinder, Kevin R., et al.
Publicado: (2017)

Potential Refinement of Recurrence Score by pSTAT3 Status
por: Grinshpun, Albert, et al.
Publicado: (2022)

TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth
por: Shen, Jiliang, et al.
Publicado: (2016)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

pSTAT1 Is Activated during the Progression of IgA Nephropathy
por: Tao, Jianling, et al.
Publicado: (2022)

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
por: Pizzuti, Laura, et al.
Publicado: (2019)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2019)

CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
por: Anderson, Enyia R., et al.
Publicado: (2022)

Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer
por: Yang, Chunmei, et al.
Publicado: (2013)

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
por: Bouwer, Nathalie I., et al.
Publicado: (2022)

Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries
por: Henson, Katherine E., et al.
Publicado: (2020)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
por: Ratosa, Ivica, et al.
Publicado: (2022)

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2021)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow‐up
por: De Strooper, Lise M.A., et al.
Publicado: (2018)

The assessment of correlation and prognosis among (18)F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients
por: Kaida, Hayato, et al.
Publicado: (2018)

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
por: Tesch, Hans, et al.
Publicado: (2018)

Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis
por: Pérez-Baos, Sandra, et al.
Publicado: (2019)

Dynamic Changes in pStat3 Are Involved in Meiotic Spindle Assembly in Mouse Oocytes
por: Haraguchi, Seiki, et al.
Publicado: (2020)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
por: Lin, Zhongjie, et al.
Publicado: (2020)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Use of thermo‐coagulation as an alternative treatment modality in a ‘screen‐and‐treat’ programme of cervical screening in rural Malawi
por: Campbell, Christine, et al.
Publicado: (2016)

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
por: Pan, Zhenyu, et al.
Publicado: (2016)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pog2fcrh0sq6be58c62m2ndn41